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ABSTRACT OF THESIS 
 
 
 
 
MODULATION OF HIGH AFFINITY HORMONE BINDING TO LH/CG 
RECEPTOR 
 
 
Precise control of physiological phenomena is performed by various kinds of receptor 
mediated signaling. The vast majority of receptors belong to the superfamily of G protein 
coupled receptors (GPCRs), which form one of the largest protein families. In the 
classical model of GPCR signaling, stimulation of seven transmembrane spanning GPCR 
leads to the activation of heterotrimeric G proteins, which dissociate into α and βγ 
subunits. The subunits activate effector molecules, which include second messenger 
generating systems, giving rise to various kinds of cellular responses. The LH/CG 
receptor is a member of the glycoprotein hormone receptor family along with the FSH 
and TSH receptors, which belongs to the GPCR superfamily. Human chorionic 
gonadotropin (hCG) binds to the exodomain of LH/CG receptor and the resulting hCG-
exodomain complex is thought to interact with the endodomain of the receptor to bring 
about hormone signal.Unfortunately, little evidence is available for the precise hormone 
contact points in the exo domain and endo domain of the receptor. The affinity of 
hormone binding to the exodomain was enhanced when the endodomain was truncated. 
This suggests that the endodomain modulates the hormone binding to the exodomain of 
the receptor. To understand this, the role of exoloop 2 on the modulation of high affinity 
hormone binding to the exodomain was studied using photoaffinity labeling technique.   
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Chapter I 
Introduction 
 
G protein coupled receptors ( GPCRs ) constitute the largest and the most diverse   membrane 
proteins involved in signal transduction. Approximately 1% of the human genome encodes for 
these G protein coupled receptors (1). The Luetinizing hormone  
receptor belongs to a subfamily of glycoprotein hormone receptors within the GPCR family that 
include the receptors for FSH, TSH and hCG. hCG is structurally very similar to LH and binds 
with high affinity to the LHR and hence the receptor is referred to as LH/CGR. Both the 
LH/CGR and the FSH-R play crucial role in the reproduction of humans. Human reproduction 
has been a major worldwide concern. There are countries that suffer from the population 
explosion whereas other countries wherein families suffer from infertility and mutations of the 
receptors result in hereditary reproductive disorders (2). Understanding the interaction of the LH 
and hCG with the LH/CGR would help in the development of drugs that can be used to solve 
such problems. GPCRs account for ~ 40% of all therapeutic intervention and major GPCR 
research projects are found in the pharmaceutical industry(2,3). 
 
Glycoprotein hormones LH, FSH, TSH and hCG are the most complex agonists for GPCRs. The 
LH and hCG both bind to the LH receptor while the FSH and TSH have their own cognate 
receptors. GPCRs are activated by a wide variety of ligands including odorant molecules, light, 
peptide and nonpeptide neurotransmitters, hormones and growth factors. These glycoprotein 
hormones are heterodimers with a common α subunit and a hormone specific β subunit(4). LH 
and FSH act together to regulate gonadal functions. They are involved in the growth and 
functions of the testis and ovaries and regulation of gametogenesis and steriodogenesis(5).   
 
GPCRs have an extracellular N-terminal domain and a membrane associated C-terminal domain 
that consists of seven transmembrane helices connected by three exoloops, three cytoloops and a 
cytoplasmic tail (fig 1).  
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Figure 1. Schematic representation of GPCR 
The general structure of the seven transmembrane GPCR . 
Adapted from Ji, T. H., Grossmann, M., and Ji, I. (1998) J. Biol.Chem., 273, 17299-17302 
 
They are coupled to heterotrimeric G proteins and hence are referred to as G protein coupled 
receptors. Upon hormone binding, the hormone/receptor complex undergoes a conformational 
change and activates G protein to replace GDP with GTP in the Gα subunit. This brings about 
the activation of adenylyl cyclase and phosholipase C that results in the formation of the second 
messengers, cAMP and IP3,  respectively. These second messengers then bring about a lot of 
other cellular responses.  
 
The LH/CGR consists of two equal halves, a 341 amino acids long extracellular N terminal half 
and a 334 amino acids long membrane associated C terminal half, which includes the seven 
transmembrane domains connected by three exoloops and three cytoloops(6,7). In addition, it has 
a signal peptide of 26 amino acids.The molecular weight of mature, lacking the signal peptide, 
LH/CG-R polypeptide is calculated to be ~75,000 Daltons. However, the actual molecular 
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weight is ~85,000 Daltons due to N-glycosylation at 6 Asn residues in the exodomain. The 
endodomain is palmitoylated and phosphorylated and their roles are not fully defined.  
 
The exodomain alone is capable of high affinity hormone binding, which is modulated by the 
endodomain(8,9). This suggests that the exodomain, in particular the hormone contact sites, and 
the endodomain are intimately related to each other during the initial and secondary interactions. 
The exodomain, endodomain and the hormone ternary complex is essential for signal generation 
(10). However the precise hormone contact points in the exodomain and the endodomain are 
unclear. The hormone binding to the exodomain was improved when the endodomain was 
truncated (11-13). This suggests that the endodomain influences the hormone binding to the 
exodomain. Furthermore, the hCG appears to interact with the exoloop 2 of the LH/CGR (14).  
Ala scanning of the 20 amino acids of the exoloop 2 showed that the exoloop 2 indeed influences 
the binding of the hormone to the exodomain (9). The aim in the present work was to gain 
insight into the molecular basis of hCG binding to its receptor and how the binding is modulated 
by the exoloop 2,  and whether  hCG binds to the exoloop 2 using photoaffinity labeling. 
 
Biology of hCG and Glycoprotein hormones 
 
Gonadotropins comprise of Follicle Stimulating hormone (FSH), Luteinizing  hormone (LH), 
human Chorionic gonadotropin (hCG) and Thyroid Stimulating hormone (TSH). FSH, LH and 
TSH are secreted by the anterior pituitary gland, whereas the trophoblast cells of the human 
placenta produce hCG. hCG prevents the deterioration of the corpus luteum and thus is essential 
for the maintenance of pregnancy. These hormones are  heterodimers with a common α subunit 
and a hormone specific β subunit (4). These two subunits are non-covalently associated and are 
encoded by distinct genes (15). High-resolution structures of hCG have been reported (16-18) 
and are considered as paradigms for the entire glycoprotein hormone family. Each subunit in 
these heterodimers is folded into three loops (α1,α2,α3; β1,β2, β3) that project from a cystine 
knot located in the center. The unique β subunit of hCG has a seatbelt structure formed by an 
intramolecular disulphide bridge (Cys26-Cys110) that embraces the α2 (fig 2). 
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Figure 2. hCG Crystal structure   
Adapted from Lapthorn, A.J., Harris, D.C., Littlejohn, A., Lustbader, J.W., Canfield, R.E., Machin, K.J., Morgan, 
F.J. & Isaacs, N.W. (1994) Nature 369, 455–461  
 
There have been numerous studies on which subunits of the hormones are involved in receptor 
binding and biological activities. Photoaffinity labeling studies and immunological experiments 
have demonstrated that both of the α and β subunits interact with the receptors . When hCG 
radioiodinated  at either the α or β subunit were incubated with the porcine granulose cells, it 
was shown that a complex formed with the LH/CG receptor regardless of whether the hormone 
was labeled in the α or β subunit after photoaffinity labeling (19).  Monoclonal antibodies 
against the α or the β subunit blocked the formation of the LH/CG R complex, suggesting that 
both subunits of hCG are involved in binding to the receptor. Both of the gonadotropins subunits 
are highly glycosylated with asparagines-linked (N-linked) and/or serine-linked (O-linked) 
oligosaccharides (20-23). The common α subunits are N-glycosylated at two conserved sites in 
FSH and CG, and one in LH. Unlike other gonadotropins, the hCG β subunit has four additional 
O-glycosylation sites (22). The importance of carbohydrates on the glycoprotein hormones have 
hCG α subunit  hCG β subunit  hCG α &β subunit 
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been implicated in the hormonal stability, secretion, assembly, receptor binding and 
steroidogenesis. When carbohydrates are removed from hCG by anhydrous hydrogen fluride 
(HF), the resulting dg-hCG fully maintained its receptor binding and immunological activities 
but lost its cAMP and progesterone inducibilities (24-26).   
 
Function of Gonadotropins: 
 
In females gonadotropins control the development of the ovarian follicles, the release of oocytes 
from the follicles and the transformation of the ovulated follicles into the corpus lutea (27-29). 
Follicles consist of an outer layer of theca interna cells, an inner layer of granulose cells and an 
oocyte-cummulus complex (fig 3). Diverse communications between these follicular cells and 
the pituitary gland, via gonadotropins, steriodogenesis and production of gonadal peptides, 
maintain the continous development of follicles in a cyclic pattern. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Graafian follicle 
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During the normal cycles of follicular development, ovulation occurs in two phases- Follicular 
phase and Luteal phase (fig 4). The early follicular phase is characterized by high levels of FSH 
and low levels of LH, estradiol and progesterone, which are related to the pulsative secretion of 
hypothalamic gonadotropin releasing hormone (GnRH) (29-31). FSH activates its receptor, 
which is present in granulosa cells of the ovarian follicles, causing an elevated level of cAMP in 
the cytosol (32). This signal is largely responsible for stimulating follicular growth, controlling 
up- and down- regulation of FSH receptor levels, stimulating the activity of aromatases to 
synthesis estradiol and inducing LH/CG receptor expression (32,33). The LH/CGR is present on 
both theca and granulose cells. Theca cells produce androstenedione, an androgen precursor, 
from cytoplasmic cholesterol, which is regulated by LH and cAMP levels (27). Androstenedione 
diffuses into granulose cells and is aromatized into estrogens. The aromatase activity in the 
granulose cells is regulated by FSH in immature follicle, and by both LH and FSH in mature 
follicles (34). Both cells contain progesterone which is secreted or used as the precursor of 
estrogens.  
 
By the mid to the late follicular phase, estradiol secretion is increased and FSH secretion is 
suppressed. The increased estradiol and progesterone levels in plasma results in  markedly 
increased secretion of LH. This LH surge triggers granulose cell disaggregation and subsequent 
release of the ovum. After ovulation both the granulosa and theca cells are luteinized to form the 
corpus luteum. The corpus luteum is rich in LH/CGR and produce mainly progesterone in a LH 
dependent manner (28). In normal menstrual cycle, the corpus luteum functions from 12 to 16 
days and then regresses. 
 
In a fertile cycle, hCG secreted from the syncytiotrophoblast maintains the corpus luteum 
function by sustaining the plasma levels of estradiol and progesterone through cAMP mediated 
protein kinases (35, 36). The hormone is detected a few days after implantation (37). The hCG 
levels reach their highest level in plasma at about 10-12 weeks (100,000mIU/mL) and decrease 
during the second and third trimesters (38). hCG also induces relaxin secretion from corpus 
luteum in the early stages of pregnancy, which may play an important role in maintaining 
pregnancy.  
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When fertilization does not occur, the corpus luteum produces a lower amount of estradiol and 
progesterone and becomes regressed during the late luteal phase. This decline in ovarian steroids 
leads to an increase in GnRH. GnRH stimulates FSH release, which initiates the next cycle of 
follicular maturation.    
 
Figure 4. Menstrual Cycle 
http://www.wisc.edu/ansci_repro/lec/lec_11/lec11fig.html#figure 5 
 
Receptors 
 
G protein coupled receptors: 
 
Nearly 2000 GPCRs have been reported since bovine opsin was cloned in 1983 (39). They are 
classified into over 100 subfamilies according to the sequence homology, ligand structure and 
receptor function. All GPCRs contain seven transmembrane spanning regions with their N-
terminal segment on the exoplasmic side and their C-terminal segment facing the cytosolic side 
of the plasma-membrane. Binding of a ligand to a GPCR causes a conformational change that 
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allows the receptor to bind to specific G proteins. The activated G protein stimulates enzymes 
like adenylyl cyclase, which  produces second messengers that bring about cellular responses. 
GPCRs are involved in the recognition and transduction of messages as diverse as photons, Ca 
2+, neurotransmitters, biogenic amines and small molecules including amino acids, peptides, 
nucleotides as well as proteins. The size of the ligands ranges from 35kD to less than a few 100 
daltons. Interestingly, a weak correlation exits such that the larger the ligand, the longer the N-
terminal extension of the receptor. For example, the N-terminal extensions of the glycoprotein 
hormone receptor are the largest with approximately 300 amino acids, in comparison to the 11-
30 amino acids long N-terminal extensions of adrenergic receptors (40).  
 
A vast  number of biological receptors that are coupled to G proteins have been cloned and 
characterized (table I). All these receptors have in common a central core of seven 
transmembrane helices connected by three exoloops and three cytoloops. Two cysteine residues 
(one in exoloop 1 and other in exoloop 2) are conserved in most GPCRs, form a disulfide bond, 
which might be involved in the stabilization of a conformation of the domains that is required for 
its activity. Each of the seven transmembrane helices is generally composed of 20-27 amino 
acids, while the N-terminal segment (7-595 amino acids), loops (5-230 amino acids) and C-
terminal segment (12-359 amino acids) vary in size indicating their diverse structures and 
functions. 
 
Glycoprotein hormone receptors: 
 
The glycoprotein hormone receptors consists of two roughly equal halves, a 350-400 amino acid 
N-terminal segment and an approximately 300 amino acid membrane associated segment. The 
N-terminal half alone is capable of high affinity hormone binding, whereas the membrane 
associated half is the site of receptor activation and signal generation (8). The N-terminal domain 
has 8-9 Leu-rich repeats. These Leu-rich repeats are thought to form a crescent with the concave 
inner surface consisting of β sheets, which may bind ligands (41, 42). In addition to the Leu-rich 
crescent, the N-terminal region of the N-terminal segment contacts the hormone (43). Although 
the N-terminal segment alone is capable of high affinity ligand binding, this is modulated by 
exoloops of the receptor (44).  
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Existing evidence suggests that glycoprotein hormones initially bind to the exodomain  of the 
receptor with high affinity and hormone specificity and then the hormone-receptor complex is 
thought to interact with the endodomain of the receptor which then brings about signal 
generation.  
 
LH/CG receptor: 
Figure 5. LH/CG Receptor  
 
LH/CG-R is encoded by a single copy gene in rats (45) and two genes in humans (46). It is found 
mainly in the gonads but also in other organs and tissues like brain, thyroid, prostate, uterus, 
placenta, fallopian tubes, fetal membranes and lymphocytes (47). LH/CG-R was also observed in 
benign breast region lesions, malignant breast tumors and other cancer cells. Unlike most G 
protein coupled receptors, it is comprised of an extremely long extracellular N-terminal half of 
341 amino acids and a membrane associated C-terminal half of 334 amino acids (6,7) (fig 5). 
The endodomain is palmitoylated and phosphorylated and their roles are not fully defined. Using 
photoaffinity labeling studies with receptor peptides, it has been shown that both halves of the 
receptor have hormone contact points. The N-terminal half alone is capable of affinity hormone 
binding (11-13) with no hormone action (13,48). In contrast, the C-terminal half is capable of 
low affinity hormone contact with cAMP induction (13,48).  
 
 
                                                            15                                                                         
 
Figure 6.a. Ternary complex 
 Adapted form Ji, T.H., Grossmann, M., and Ji, I. (1998) J. Biol.Chem., 273, 17299-17302 
 
The exodomain binds the hormone with high affinity without hormone action but cannot 
generate hormone signal. Growing evidence suggests that glycoprotein hormone initially bind to 
the exodomain and the resulting exodomain-hormone complex undergoes conformational change 
(49) and interacts with the endodomain of the receptor (fig 6.a.). This secondary interaction is 
thought to generate signal (8,50-51). However the high affinity hormone binding at the 
exodomain is modulated by the endodomain (52). The LH/CG-R generates two distinct signals, 
one to activate adenylyl cyclase and produce cAMP and the other to activate Phospholipase C 
and produce diacylglycerol and inositol phosphates (Fig 6.b.). Despite the importance, only 
limited information is available concerning the precise hormone contact residues and sites in the 
exodomain. 
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Figure 6.b. GPCR Cell Signaling 
 
Studies involving truncation, deletion and site-directed mutagenesis indicate that several regions 
of the exodomain are crucial for hormone binding. Sequence comparison and modeling suggest 
that the exodomain contains Leu/Ile rich repeats (LRRs) (6), which are flanked by short N-
terminal and C-terminal regions (fig7). LRRs are a structural motif in proteins like ribonuclease 
inhibitor and also common in a large family of proteins. Based on the structure of the 
ribonuclease inhibitors, an issue was raised that the inner lining of the LRRs in LH/CG-R and 
FSHR might contact the respective hormones (42,53-55), in particular, with the concave side of 
the hormone (16). It was shown that the β strand Leu and Ile residues in all LRRs in the human 
LHR and FSHR are crucial contact sites (56), especially the LRR2 and LRR4 are important for 
hormone binding. Affinity labeling studies showed that the N-terminal region of the LRR4 
α
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interacts with hCG, preferentially the α subunit and the hCG/LRR4 complex interacts with the 
exoloop 2 of the endodomain (67).   
 
The seven to nine Leu-rich repeats in the exodomain, are generally thought to form 1/3 donut-
like structure and interact with the hCG. The resulting hCG –exodomain complex then interacts 
with the endodomain (exoloop 2) which is results in the signal generation. 
But it was unclear whether this alone could be sufficient for the hormone action. To address this, 
first residues in the exon 9-10 junction of LHR, junction sequences of FSHR and TSHR were 
aligned. A homology was found from Tyr 253 to Phe 260. In addition, the sequence corresponding 
to LHR Arg 261 to Gln 268 is highly conserved within each receptor type among species. So, the 
exodomain was Ala scanned and receptor peptides were used for photoaffinity labeling and 
affinity cross-linking.  
 
 
 
 
 
 
 
 
 
 
Figure 7. Leucine rich repeat 
 Adapted from Jeoung, M., Phang,T., Song, Y., S., Ji, I and Ji T., H (2001) J. Biol. Chem. 276, 3443-3450 
 
It was shown that the C-flanking sequence (the hinge region), Thr250 – Gln 268  (58) of the LRRs 
specifically interacts with hCG, preferentially hCGα. This interaction was shown to be inhibited 
by exoloop 2 and not by exoloops 1 and 3. This suggested the importance of the ternary complex 
that exists between the exodomain of the receptor, hCG and the endodomain of receptor (59). 
Thus the endodomain was seen to modulate the hormone binding to the exodomain. Further a 
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defined epitope on the hCG was shown to interact with the exoloop 2 of the LH/CG-R (14). Ala 
scanning of the 20 amino acids of the exoloop 2 showed that the exoloop 2 indeed influences the 
binding of the hormone to the exodomain (52).  
 
Both the LH/CG-R and FSHR play crucial role in the reproduction of humans. Human 
reproduction has been a major worldwide concern. Approximately 16% of the American families 
experience infertility problems and mutations of these receptors result in hereditary reproductive 
disorders. Therefore, these hormones and LH/CG-R have been implicated for the treatment of 
fertility and infertility disorders. GPCRs account for ~ 40% of all therapeutic intervention and 
major GPCR research project are found in the pharmaceutical industry (2,3) 
 
 The wealth of information gained over the last decade has substantially improved our 
understanding of GPCR function. However the precise identification of the regions of hormone 
and receptors that are capable of interaction and /or triggering transmembrane signaling remains 
incomplete (60). The further clarification of these mechanisms represents a daunting task 
coupled with efforts aimed at obtaining high-resolution X-ray crystals. 
 
The high affinity hormone binding to the N terminal extracellular domain of the GPCR and the G 
proteins activated by the intracellular regions of the receptors suggests that upon hormone 
binding, a portion of the hormone or the receptor’s extacellular regions might interact with the 
exoloops of the GPCRs in ligand binding. The possibility of hormone-receptor interaction 
through  the exoloops of GPCRs has already been reported. The exoloop 2 of the LH/CGR 
consisting of 20 amino acids connects the TM 4 and TM 5 domains. The sequence alignment is 
as shown in fig8. The 20 amino acids sequence  
Ser484 – Asn485 – Tyr486 – Met487 – Lys488 – Val489 – Ser490 – Ile491 – Cys492 – Phe493 – Pro494 – 
Met495 – Asp496 – Val497 – Glu498 – Thr499 – Thr500 – Leu501 – Ser502 – Gln503, is highly conserved 
among different species suggesting its importance.  
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  484                                                                                                    503 
LHR Human       S   N   Y   M   K   V   S   I   C   F   P   M   D   V   E   T   T   L   S   Q 
LHR Mouse       *    S    *    *    *    *    *   *   *   L   *    *    *    *    *    *   *   *    *   *  
LHR Rat             *    *    *    *    *    *    *   *   *   L   *    *    *    *    *    S   *   *    *   * 
LHR Bovine       *    *    *    *    *    *    *   *   *   L   *    *    *    *    *    S   *   *    *   * 
LHR Pig             *    S    *    *    *    *    *   *   *   L    *    *    *    *    *   *   *   *    *   * 
LHR Calja          *    *    *    *    *    *    *   *   *   *    *    *    *    *    *    *   *   *   *   * 
Q14751              *    *    *    *    *    *    *   *   *   *    *    *    *    *    *    *   *   *    *   * 
Q15996              *    *    *    *    *    *    *   *   *   *    *    *    *    *    *    *   *   *    *   * 
 
Fig8.Comparison of exoloop 2 sequences among different species 
 
order to identify the amino acid residues that are crucial for the hormone binding and signal 
generation Ala scanned the 20 amino acids long exoloop 2. They found that the high affinity 
hormone binding at the exodomain is constrained by the amino acids Ser484, Asn485, Lys488, 
Ser490 and Ser499 (61). As a result of this, the exodomain attains maximal affinity for hormone 
binding when the endodomain is truncated and cAMP induction is disengaged. It also 
demonstrated that exoloop 2 of LH/CG R influences the hormone binding affinity, the affinity 
for cAMP induction and maximal cAMP production, probably by the interaction of the exoloop 
2 with the exodomain and other parts of the endodomain like the TM 6 and TM 7.  
 
 However, one may raise an issue as to whether the Ala substitution effects were due to the 
changes in the overall structure of the receptor rather than the changes in the structure close to 
the substituted residues. But there is growing evidence that support local conformational changes 
induced by substitution of a single amino acid. The Cys residue in the exoloop 2, Cys492 is highly 
conserved among the different species and it has been implicated to form a disulphide bridge 
with the Cys416 present in exoloop 1, in other GPCRs (62).  However, in LH/CG R the C492A 
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substitution resulted in the loss of surface expression but not the high affinity hormone binding. 
This shows that the Cys residue in exoloop 2 is involved in surface expression but is not 
important for hormone binding. Computer modeling suggests that Ser484, Asn485, Lys488, Ser490 
and Ser499 may be positioned on one side of exoloop 2. Two models were constructed (fig9). In 
both models these residues are clustered together in the middle of the exoloop 2 suggesting their 
role in binding affinity. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Computer models of exoloop 2  
Adapted from Ryu K-S, Beauchamp J, Tung C-S, Isaacs NW, Ji I, Ji TH.(1998) J. Biol. Chem. 273, 6285-
6291  
All these results support the significance of exoloop 2 in the modulation of the hormone binding 
to the exodomain of the LH/CG R. The next question is whether or not the crucial exoloop 2 
actually interacts with the hormone. To test if the region actually interacts with the hormone, 
hCG was photoaffinity labeled with a peptide mimic corresponding to Ser484 – Gln503 of the 
receptor. 
Chapter II 
Materials and Methods  
Materials: 
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The N-hydroxysuccinimide (NHS) ester of 4-azidobenzoic acid (AB) was synthesized as 
described previously (63). The N-hydroxysulfosuccinimide esters of ethylene 
glycobis(sulfosuccinimidyl succinate) (SES) was purchased from Pierce. hCG CR127 and 
hCG subunits were supplied by the National Hormone and Pituitary Program.  Receptor 
peptides were synthesized and N-acetylated and C-amidated by Biosynthesis (Lewisville, 
TX). They were purified on a Vydac C18 high performance liquid chromatography column 
using a solvent gradient from 100% of 0.1% trifluoroacetic acid in water to 20% of 0.1% 
trifluoroacetic acid in water and 80% 1-propanol. The peptide mimics include the wild type 
receptor peptide corresponding to the LHR sequence of 484-503 (exoloop 2), 246-269 (hinge 
region) and receptor peptides in which one of the amino acid residue was substituted by Bpa 
like LHR484-503 F493Bpa, LHR96-115 C106Bpa, LHR96-115 S104Bpa and LHR96-115 
G109Bpa. All these were purchased from Genemed Synthesis Inc. South San Francisco 
California, USA.  
 
     Radioiodination 
 
Introduction: 
Radioiodination remains one of the extensively used methods for labeling compounds of 
medical and biological interest. The radionuclide I125, with its 60 days half-life, has been the 
radionuclide of choice for producing labeled compounds for in vitro assays (63). Among 
several reactions used for I125 labeling, the Chloramine-T (N-chloro-p-toluenesulfonamide) 
oxidation, developed by Hunter and Greenwood in 1962 (64), has proven to be the method of 
choice for various compounds containing tyrosyl residues. Thus effective radioiodination can 
take place in many compounds and Chloramine labeling often results in biomolecules with 
high specific activities. The principle of labeling is based on the “in situ” oxidation of iodide 
to atomic iodine and its nucleophilic substitution into phenol rings in ortho position located 
in the hydroxyl group of tyrosyl residues of proteins. However, damage to target molecules is 
a matter of concern while using this radiolabeling technique.  
 
Reagents: 
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Sodium iodide-125 (I125) was purchased from Amersham Pharmacia Biotech, UK.                                      
Chloramine-T was purchased from Sigma (Sigma Chemical Company, St. Louis, MI, USA) 
and stored in a dry place at room temperature. Shortly before labeling, a stock solution was 
prepared at a concentration of 1mg/mL in 10mM Na2HPO4 and 0.9% NaCl (pH 7.4) (PBS). 
Sodium metabisulfite stock solution was also prepared at a concentration of 2.5mg/mL in 
PBS that was used as a reducing agent to stop the reaction. The target peptides were 
dissolved in 0.1M sodium phosphate (pH 7.5) at a concentration of 30ug/40uL.  
 
Radiolabeling and reaction conditions 
1mCi of Na 125I in 10uL of 0.1M NaOH and 7uL of chloramine-T (1ug/uL) in 10mM 
Na2HPO4 and 0.9% NaCl (pH 7.4) was added to 30ug of peptide in 40uL of 0.1 M Sodium 
phosphate (pH 7.5). After 20 s, 7uL of sodium metabisulfite (2.5mg/mL) in PBS was 
introduced to terminate the radioiodination.  
 
Gel permeation of labeled molecules: 
Gel permeation was done to remove unbound I125. For this purpose radioiodinated peptide 
solution was mixed with 60uL of 16% sucrose solution in PBS and fractionated on Sephadex 
Superfine G-10 column (0.6 * 15 cm) previously saturated with elution buffer (PBS). Elution 
was done with PBS and the fractions were counted for radioactivity. The specific activity 
was calculated. 
 
Derivatization with NHS-AB or SES was done by freshly dissolving the the crosslinking 
reagent in dimethyl sulfoxide to a concentration of 50mM in 0.1M sodium phosphate (pH 
7.5) to a concentration of 20mM. This reagent solution was immediately used to derivatize 
receptor peptides. In the dark, 10uL of NHS-AB or SES was added to the 30ug of peptide in 
40uL of 0.1 sodium phosphate (pH 7.5). The mixture was incubated for 30 min with the 
cross-linking reagent.  
Radioiodination of hCG: 
The following protocol is for the radioiodination of hormone only, NOT peptide. It is set up 
stoichiometrically such that one I 125 molecule will react with one hormone molecule. 
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Reagents: 
Sodium iodide-125 (I125) was purchased from Amersham Pharmacia Biotech, UK.                                    
Chloramine-T was purchased from Sigma (Sigma Chemical Company, St. Louis, MI, USA) 
and stored in a dry place at room temperature. Shortly before labeling, a stock solution was 
prepared at a concentration of 0.3mg/mL in 10mM Na2HPO4 and 0.9% NaCl (pH 7.4) 
(PBS). Sodium metabisulfite stock solution was also prepared at a concentration of 
0.66mg/mL in PBS that was used as a reducing agent to stop the reaction. The target 
hormone was dissolved in 0.1M sodium phosphate (pH 7.5) at a concentration of 3ug/40uL.  
 
Radiolabeling and reaction conditions are similar to radioiodination of peptide and to purify 
the iodinated hormone, gel permeation was carried out as described above but on a Sephadex 
G-50 superfine column. 
 
     Storage:  
I125 labeled peptides and hormone were stored in 4° C with the tubes containing 
photosensitive peptides wrapped with aluminium foil.  
 
Special Considerations while working safely with I125 (Amersham pharmacia biotech): 
 
1. Freezing or acidification of solutions containing iodide ions can lead to the            
formation of volatile elemental iodine. 
2. Opening a vial of high radioactive concentration of I125 can produce active aerosols. 
3. Some iodo-compounds can penetrate surgical rubber gloves; two pairs or polythene 
alternatives are recommended. 
4. In the event of suspected contamination of personnel, block the thyroid by the              
      administration of potassium iodate (170mg) or potassium iodide (130mg).  
5. Spills of I125 should be stabilized with alkaline sodium thiosulphate solution before 
commencing decontamination.  
 
Although the method is considered easy and reliable, the damage to target molecules due 
to excess of oxidant is of major concern. Loss of immunological activity in proteins is 
 
                                                            24                                                                         
thought to be due to Chloramine-T action on the disulphide bridges and sulfhydryl 
groups, often giving rise to macro molecular protein complexes (64,65). In summary, 
radioiodination of biomolecules by the Chloramine-T method is the best method if 
excessive use of oxidizing agent is avoided.  
 
B. Photoaffinity labeling: 
 
 Photoaffinity labeling is a technique that makes use of  capacity of certain compounds to 
make covalent bonds after UV irradiation and it overcomes the non-specificity of using 
homobifunctional reagents for crosslinking by eliminating random collisional cross-links. 
The general protocol for photoaffinity labeling is as shown in the figure 10.  
 
             
PhotoaffinityLabeling Protocol
Expose to 
UV
Add loading 
buffer
Boil samples
Incubate
SDS-PAGE
 
 
 
Figure 10. Diagramatic representation of Photoaffinity Labeling 
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Method 1:   
 
Photoaffinity labeling using N-hydroxysuccinimide ester (NHS): 
                      
             
                            
 
Figure 11. Structure of NHS-AB 
 
To photoaffinity label hCG with 125I-LHR484-503 , the receptor peptide was derivatized with 
N-hydroxysuccinimide ester of 4-azidobenzoic acid, (NHS-AB)  to produce NHS-AB-125I-
LHR484-503  as described earlier.  Disposable glass tubes were siliconized under 
dimethlydichlorosilane vapor for 4 hours and autoclaved. In each of the tubes, 20uL of PBS, 
10uL of hCG in PBS (7ng/uL ) and 10uL of AB- 125I-LHR 484-503 (10ng/uL) in PBS were 
mixed and incubated at 37°C for 90 min in the dark, irradiated with Mineralight  R-52 UV 
lamp for 1 min as described previously (66) and solubilized in 2%SDS, 100mM dithiothreitol 
and 8M urea to cleave disulfides and dissociate interacting components of complexes. The 
samples were electrophoresed on 8-12% polyacrylamide gradient gels. Gels were dried on 
Model 583 gel dryer (Bio-Rad), which was exposed to a molecular imaging screen (Bio-Rad) 
overnight. The imaging screen was scanned on a Model GS-525 Molecular Imager System 
Scanner (Bio-Rad).   
 
 
 
 
Method II: 
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   Photoaffinity labeling with Bpa as the photoactive group: 
 
A radioiodinatable peptide, LHR484-503, that had a photolabile para-benzoyl-L-phenylalanine 
(Bpa) residue at 493 position, instead of the phenylalanine originally present, was used to 
photoaffinity label hCG. For this purpose, the Bpa peptide was radioiodinated as described 
previously.  
     Advantages of using Bpa as a photoactivable reagent: 
–Excited state is inert towards water 
–Chemical stability 
–Can be incorporated at a defined position of peptides during synthesis 
    
  
 
 
 
 
Figure 12. Structure of Bpa 
Adapted from Gyorgy Dorman and Glenn D. Prestwich (1994) Biochemistry, 33,5661-5671 
 
Labeling and reaction conditions: 
The following solutions were sequentially introduced into siliconized tubes: 30uL of 
radioiodinated Bpa peptide and 10uL of hCG. The mixture was incubated for 90 min at 37° C 
in the dark, irradiated with Mineralight R-52 UV lamp for 1 min and solubilized with 2% 
SDS, 100mM dithiothreitol and 8M urea to cleave disulfides and dissociate interacting 
components of complexes. The samples were  electrophoresed on 8-12% polyacrylamide 
gradient gels. Gels were dried on Model 583 gel dryer (Bio-Rad) ), which was exposed to a 
molecular imaging screen (Bio-Rad) from 24-36 hours depending on the radioactivity present 
in the gel. The imaging screen was scanned on a Model GS-525 Molecular Imager System 
Scanner (Bio-Rad).  The photoaffinity group of choice is p-benzoylphenylalanine (Bpa), 
activated at 300-350 nm. However it has to be taken into account that Bpa is a bulky 
molecule that can alter the binding of the peptide to receptor. To make a replacement of other 
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aminoacid to Bpa, it is better to replace the hydrophobic amino acid in order to try to 
preserve the activity.  
 
C. Affinity crosslinking: 
 
Introduction: 
In affinity crosslinking, radioactively labeled ligands are allowed to bind to the receptor and 
the resultant ligand-receptor complex, along with all other protein molecules present in the 
system, is subject to covalent crosslinks by the introduction of homobifunctional reagents 
called crosslinkers. Example of a crosslinker is ethylene 
glycolbis(sulfosuccinimidylsuccinate) (SES) also abbreviated as (Sulfo EGS). 
  
 
 
Figure 13. Structure of SES 
Adapted from www.usalchemy.com 
 
Properties: 
1. M.W. 660.5 
2. Primary amine reactive  
3. Hydroxylamine cleavable 
4. Water soluble 
 
      Method: 
In siliconized tubes, 20uL of PBS, 10uL of hCG and 10uL of 125 I-LHR 484-503 were mixed 
and incubated at 37° C for 90 min. After incubation, 5uL of 0.3mM SES in dimethyl 
sulfoxide was added to each tube and further incubated at 25° C for 20 min. The samples 
were boiled for 2 min in 2% SDS, 100mM dithiothreitol and 8M urea to cleave disulfides and 
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dissociate interacting components of complexes. The solubilized samples were 
electrophoresed on 8-12% polyacrylamide gradient gels. The gels were dried on a Model 583 
Gel Dryer (Bio-Rad) and exposed to molecular imaging screen (Bio-Rad). The imaging 
screen was scanned on a model GS-525 Molecular Imager System Scanner (Bio-Rad). 
 
Advantages and Disadvantages of photoaffinity labeling and affinity crosslinking: 
 
The primary advantage of photoaffinity labeling over affinity crosslinking is that formation 
of a covalently crosslinked complex is limited to the ligand and the receptor in photoaffinity 
labeling in other words is highly specific, whereas in affinity crosslinking formation of 
crosslinked complexes is random and non-specific. However, one major advantage of affinity 
crosslinking is the complex is not light sensitive and hence reaction need not be carried out in 
the dark. 
 
D. Sodium dodecyl sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE): 
 
Introduction:  
 
Electrophoresis is the migration of charged molecules in solution in response to an electric 
field. Their rate of migration depends on the strength of the field; on the net charge, size and 
shape of the molecules and also on the ionic strength, viscosity and temperature of the 
medium in which the molecules are moving. As an analytical tool, electrophoresis is simple, 
rapid and highly sensitive. It is used analytically to study the properties of a single charged 
species, and as a separation technique. 
 
SDS-PAGE: 
 
A technique for analyzing mixtures of proteins or for estimating protein molecular weights, 
involving electrophoresis in a polyacrylamide gel in the presence of the anionic detergent, 
sodium dodecyl sulphate (SDS). The SDS binds to the proteins, denaturing them and 
conferring on them a uniform density of negative charges. The denatured protein / SDS 
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complexes show a constant relationship between mobility and log (MW). The molecular 
weight of a particular protein can be assessed by comparison of its migration with those of a 
series of marker proteins of known sizes. 
 
The pore size of the gel may be varied to produce different molecular seiving effects for 
separating proteins of different sizes. In this way, the percentage of polyacrylmide can be 
controlled in a given gel. By controlling the percentage (from 3% to 30%),  pore sizes can be 
modulated, usually to resolve molecules of 5 to 2,000 kdal. This is the ideal range for gene 
sequencing, protein, polypeptide, and enzyme analysis. Polyacrylamide gels can be cast in 
non gradient or with varying gradients. Gradient gels provide continuous decrease in pore 
size from the top to the bottom of the gel, resulting in better defined bands. Because of this 
banding effect, detailed genetic and molecular analysis can be performed on gradient 
polyacrylamide gels. Polyacrylamide gels offer greater flexibility and more sharply defined 
banding than agarose gels.  
    
   
 
 
Figure 14. Structure of SDS 
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Figure 15. General Schematic Representation of SDS-PAGE 
 
Method: 
The solubilized samples were loaded onto a 8-12% polyacrylamide gradient gel. The 
electrophoresis was carried out initially at 60V for 2 hours and then at 100 for 8hours. The 
gel was fixed in 33% methanol for 45min and dried using Model 583 Gel dryer (Bio-Rad).  
 
E. Deglycosylation and Glu C digestion of hCG: 
         1.Deglycosylation of iodinated hCG: 
 
Introduction: 
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Glycosylation of glycoprotein hormones begins in the rough endoplasmic reticulum (RER). 
The figure 16 below shows the glycosylation sites on the human glycoprotein hormone - 
and -subunits. The subunit proteins are indicated by the horizontal bars and the N-linked 
oligosaccharides by the branch-like structures. The lollipop indicates O-linked glycosylation 
sites in CG . The amino acid residue to which the oligosaccharide is attached is indicated by 
the numbers under each glycosylation site. 
 
  
 
 
Figure 16. Glycosylation sites in Glycoprotein hormones 
adapted from Arch Med Res. 2001 Nov-Dec;32(6):520-32. Review.) 
 
Oligosaccharide structures of glycoprotein hormones play an essential role in many of the 
functional characteristics of the molecule. They are important not only for the folding, 
assembly, conformational maturation and posttranslational processing of the subunits but 
also for heterodimer secretion, metabolic fate, interaction with cognate receptor and signal 
transduction. Chemical or enzymatic treatments to remove the N-glycans on hCG reveal that 
removal of the carbohydrate moieties has little effect on receptor binding. So, to check the 
binding of hCG without the sugars to LH/CG R, deglycosylation of iodinated hCG was 
carried out.   
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Materials and Method: 
 
Peptide:N-glycosidase F (PNGase F) was bought from New England BioLabs Inc and O-
Glycosidase from Roche Diagnostics.  
PNGase is an amidase with an apparent molecular weight of 36,000Daltons. It cleaves 
between the innermost GlcNAc and Asn residue of high mannose, hybrid and complex 
oligosaccharides from N-linked glycoproteins.  
 
 
 
O-Glycosiadase is used to release the Gal β (1-3) GalNAc from O-glycans. Bindings to 
serine as well as to threonine are hydrolysed. 
 
 
 
 
To 10uL iodinated hCG the following was added, 5uL of 40mM DTT and 10uL of 1M Urea. 
The mixture was boiled for 4 min, cooled and then added 2uL of PNGase F and 1uL of O-
Glycosidase. Incubated the samples for 18 hours at 37° C. The samples were loaded onto 
15% polyacrylamide single concentration gel. Gel was dried on a Model 583 gel dryer and 
exposed to molecular imaging screen (Bio-Rad) overnight. The imaging screen was scanned 
on a Model GS-525 Molecular Imager System Scanner (Bio-Rad).   
 
 
2. Deglycosylation and Glu-C digestion of iodinated hCG photoaffinity labeled with      
    peptide: 
 
Introduction: 
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Endoproteinase Glu-C cleaves at Glutamic acid – X and Aspartic acid – X where X is any 
other amino acid residue. By treating the hCG photoaffinity labeled with peptide for 
deglycosylation and further to Glu C digestion, the fragments obtained can be analyzed by 
Mass Spectrometry to identify labeled amino acid residues.  
 
     Materials and Method: 
 
Glu C was purchased from Roche Diagnostics. The iodinated hCG was incubated with wild 
type peptide (LHR96-115 G 109Bpa) for 90 min at 37° C. The samples were irradiated with 
Mineralight R-52 UV lamp for 1 min. Added 10uL of 1M urea and 5uL of 20mM DTT to the 
above mixture and boiled for 4 min. The sample was cooled down and 8% Glu-C was added 
and incubated at room temperature for 16 hours. The samples were solubilized in 2%SDS, 
100mM dithiothreitol and 8M urea to cleave disulfides and dissociate interacting components 
of complexes and  electrophoresed on 15% polyacrylamide single concentration gels. Gels 
were dried on Model 583 gel dryer (Bio-Rad), which was exposed to a molecular imaging 
screen (Bio-Rad) overnight. The imaging screen was scanned on a Model GS-525 Molecular 
Imager System Scanner (Bio-Rad).   
 
Drawbacks of the enzymatics treatments: 
1. The treatments may damage the protein backbone 
2. Removal of the oligosaccharides may be incomplete. 
 
 
Chapter III 
Results and Conclusion 
A.1. Radioiodination of peptide: 
Radioiodination of compounds by the Chloramine-T method results in biomolecules with high 
specific activities. The following figure shows the radioiodiantion of the LHR484-503 F 493 Bpa 
peptide. The 125I is incorporated on the Tyrosine, 10 fractions were collected.  A sharp peak 
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which corresponds to the hottest fraction is number 3 with 408,477cpm/2uL. The specific 
activity is 10,667.2 cpm/ng. The fraction number 3 was stored in a glass tube wrapped with 
aluminium foil to prevent exposure to light until use. 
 
  
    
       
       
Fraction CPM  
1 215  
2 125666  
3 408477  
4 188195  
5 148293  
6 118230  
7 116579  
8 104017  
9 98831  
10 82867  
                 Total 1391370 
 
 
 
Total cpm = 1391370 * 230      
 
Specific activity = 10667.2 cpm/ng    
       
Fraction 3 has 408477 * 230 = 93949710 cpm   
 
Therefore ng of peptide present in fraction 3 is 8807.3 ng  
       
100ng of peptide is present in 2.6uL of fraction 3   
       
       
Figure 17. Iodination of LHR484-503 F493Bpa 
 
For photoaffinity labeling using NHS-AB, the derivatized peptide is iodinated. 
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Fraction  cpm 
 
     CT(0.38umol)=1mg/1mL spb 
1 18872    SM(0.92umol)=2.5mg/1mL spb 
2 730474    SU(16%)= 0.024g/150uL spb 
3 708303    NHS-AB = 0.00065g/50uL 
4 192148    peptide = 30ug/40uL  
5 182828       
6 118560    Flow rate=200uL/4 drops 
7 40551       
8 26016       
9 12747       
10 9733       
 2040232       
         
         
         
         
         
 Total cpm = 2040232 * 200      
    = 408050000       
         
Specific Activity = total cpm/ng of peptide used    
              = 408050000/30000     
              = 13601.5cpm/ng      
Specific Activity = 13601.5cpm/ng     
Fraction 2 has 730474 cpm      
Therefore ng of peptide present is 730474 * 200/ 13601.5   
         
10741ng of peptide is present in fraction 2     
100ng of peptide is present in 1.9 uL of fraction 2    
100 ng of peptide has 1360160 cpm     
 
Figure 18. Radioiodination of NHS-AB Exoloop 2 Peptide  
 
A.2. Radioiodination of hCG: 
Radioiodination of hormone was designed such that only one 125I molecule reacts with one 
hormone molecule. Below is the figure showing the results of iodination of hCG. 6 fractions 
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were collected. There was a peak with 478016cpm/2uL of fraction 2. This fraction was stored in 
a glass tube for further use.  
       
   
   
Fraction CPM  
   
1 1500 
2 478016 
3 263100 
4 25200 
5 12488 
6 3103 
   
   
   
   
 
Total cpm = 783407 * 230       
        
Specific activity = 783407 * 230 / 3,000 = 60,061.2 cpm/ng   
        
Fraction 2 has 478016 * 230 cpm = 109,943,680 cpm    
        
Therefore ng of hCG present in fraction 2 is 1830.5ng    
 
Figure 19 Iodination of hCG 
B. Exoloop 2 modulates hormone binding to LH/CG receptor: 
 
The LHR484-503 F493Bpa was radioiodinated on Tyr residue in position 486 using Na 125I and 
fractionated on a sephadex G-10 column. The peptide was incubated with hCG, exposed to UV 
light, solubilized and then separated on SDS-Polyacrylamide gel. Dried gels were analyzed on a 
phosphoimager. The hormone concentration dependent, peptide concentration dependent and the 
UV duration dependent assays were carried out. 
 
 
 
 
 
 
 
                                                            37                                                                         
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Photoaffinity Labeling of Exoloop 2 Bpa peptide 
 
 hCG was incubated with 125 I-LHR484-503 F493Bpa and irrardiated with UV. In this series, UV irradiation time (C) , 
125 I-LHR 484-503 F493Bpa concentration ( B ), or hCG concentration (A ) was varied, while the other two factors 
were kept constant. After electrophoresis of the samples, gels were dried on Model 583 gel dryer and exposed to a 
molecular imaging screen (Bio-Rad). The imaging screen was scanned on a model GS-525 Molecular Imager 
System Scanner (Bio-Rad).  
 
One major limitation of the Bpa peptide for these studies is that it is photolysable. To determine 
the photolysis and overcome this problem the UV duration dependent study was performed, 
shown in the figure 20. A striking feature observed in all the experiments performed with the 
exoloop 2 Bpa peptide was that in the second lane with no hormone in hormone concentration 
dependent assay there is labeling seen. One possible explanation is contamination during loading 
the samples onto the gel. For all these assays the first lane is 125I-hCG used as marker. To check 
if this was due to some technical error, photoaffinity labeling of S104Bpa and C106Bpa of 
LHR96-115 was carried out (fig21). From the figure it is obvious that the α  subunit of the hCG 
was labeled more than the β subunit. With increasing concentration of hormone, the intensity of 
labeling also increased.  
C 
B A 
 
                                                            38                                                                         
               
 
 
 
 
 
 
 
 
Figure 21. Photoaffinity Labeling of LHR96-115 S104Bpa and C106Bpa peptides 
hCG was incubated with 125 I-LHR 96-115 C106Bpa (A) and 125 I-LHR 96-115 S104Bpa (B)  and irrardiated with 
UV.hCG concentration was varied while the concentration of the peptide and UV irradiation time were kept 
constant. After electrophoresis of the samples, gels were dried on Model 583 gel dryer and exposed to a molecular 
imaging screen (Bio-Rad). The imaging screen was scanned on a model GS-525 Molecular Imager System Scanner 
(Bio-Rad).  
  
The bands seen in experiments with exoloop 2 Bpa peptide may represent oxidation products that 
overshadow the actual labeled α subunit. There are residues in the exoloop 2 that can possibly be 
oxidized like methionine and cysteine. One way to eliminate this potential oxidative damage is to 
replace these residues with some other amino acid like isoleucine that are resistant to oxidation. 
However we cannot exclude the possibility of these amino acid substitutions not affecting the 
global structure of the protein or the peptide. Another possible explanation for the diffuse bands 
is that the exoloop2 Bpa peptide might dimerize by itself. Compounding this problem is the Bpa 
being a highly hydrophobic bulky group. A homobifunctional crosslinker SES was used to 
crosslink the radioactively labeled Exoloop 2 Bpa peptide to hCG (diagram not shown). 
However since the crosslinking is random, formation of hormone-hormone complexes and 
peptide-peptide complexes is also possible.  
 
NHS-AB can reach and label target molecules up to 7° A. 125I-LHR 484-503 derivatized with NHS-
AB bind to hCG and when irradiated with UV, crosslinking is restricted between 125I-LHR484-503 
and hCGα or between 125I-LHR484-503 and hCGβ. The reagent however will not be able to 
crosslink one hCG subunit to another. As shown in the figure 22, NHS-AB –125I-LHR484-503 was 
C106Bpa S104Bpa 
A B 
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capable of photoaffinity labeling either hCG α or hCGβ but not both subunits at the same time to 
produce hCGαβ complex. In addition hCG α was more preferentially labeled than hCG β. One 
possible explanation for this is that the N-terminus of the LHR484-503 derivatives is < 7° A from 
the hCG α and β subunits and the peptide derivatives are bound closer to the α than β subunit.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 22. Photoaffinity Labeling of NHS-AB exoloop 2 peptide 
 
hCG was incubated with AB-125I-LHR 484-503  and irrardiated with UV. UV irradiation time (C), AB-125 I-LHR 484-503 
concentration ( B ), or hCG concentration (A ) was varied, while the other two factors were kept constant. In (D ), 
denatured hCG was incubated with increasing concentration of AB-125I-LHR 484-503 and irradiated with UV for 2 
min. After electrophoresis of the samples, gels were dried on Model 583 gel dryer and exposed to a molecular 
imaging screen (Bio-Rad). The imaging screen was scanned on a model GS-525 Molecular Imager System Scanner 
(Bio-Rad).  
 
Concentration effect of hCG and the peptide: 
When a constant amount of hCG was incubated with increasing concentrations of the NHS-AB-
125I-LHR484-503, the intensity of the labeled hCG α and β bands increased gradually and plateaued 
as shown in the fig22. A similar result was obtained when a constant amount of the peptide was 
incubated with increasing concentrations of hCG. These results show that the concentrations of 
A B 
D C 
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both of the peptide and hCG are the limiting factors for the photoaffinity labeling. The labeling 
was dependent on the hCG concentration, derivatized peptide and UV exposure and in all cases 
the hCG was preferentially labeled. In conclusion, although the NHS-AB derivatized peptide was 
shown to label the hCG preferentially the α subunit than the β subunit, the exoloop 2 Bpa 
peptide was definitely a tough one to work with and had lots of problems hard to define. 
 
Deglycosylation of iodinated hCG was carried out. Figure 23 shows this. The α band is shifted 
much lower when sample sourse treated with a glycosidase and PNGase F, which is in agreement 
to the removal of sugar molecules. Glu C digestion of the iodinated hCG after deglycosylation 
was also carried out (fig 24). It can be seen that the deglycosylation and the digestion both are 
incomplete.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Deglycosylation of 125 hCG 
 
125 I-hCG was solubilized with DTT and urea, treated with PNGase F and O-Glycosidase and incubated. After 
electrophoresis of the samples, gels were dried on Model 583 gel dryer and exposed to a molecular imaging screen 
(Bio-Rad). The imaging screen was scanned on a model GS-525 Molecular Imager System Scanner (Bio-Rad).  
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Figure 24. Glu-C digestion of deglycosylated hCG 
 
125 I-hCG was solubilized with DTT and urea and in lane 2 treated with PNGase F and O-Glycosidase and 
incubated while in lane 3 treated with PNGase F and O-Glycosidase and Glu-C and incubated. After electrophoresis 
of the samples, gels were dried on Model 583 gel dryer and exposed to a molecular imaging screen (Bio-Rad). The 
imaging screen was scanned on a model GS-525 Molecular Imager System Scanner (Bio-Rad).  
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Figure 25. Glu-C digestion of hormone incubated with peptide 
 
hCG was incubated with 125 I-LHR 96-115 G109Bpa (lanes 5 and 6) and 125 I-LHR484-503 F493Bpa (lanes 3 and 4)  and 
irrardiated with UV. Samples were solubilized with DTT and urea and incubated with Glu-C. 
After electrophoresis of the samples, gels were dried on Model 583 gel dryer and exposed to a molecular imaging 
screen (Bio-Rad). The imaging screen was scanned on a model GS-525 Molecular Imager System Scanner (Bio-
Rad).  
  
 
hCG photoaffinity labeled with peptide LHR96-115 G109Bpa or LHR484-503 F493Bpa that was 
deglycosylated and digested with Glu-C digestion is shown in figure 25. The first lane is just the 
iodinated hCG and second lane shows hCG deglycosylated and then digested with 8% Glu-C. In 
the lanes 3 to 6 the 125I hCG labeled with the peptides, and lanes 4 and 6 are the samples treated 
with glycosydidase, PNGase F and Glu-C. The lanes 1, 3 and 5 look the same because the 
peptide molecular weight is in the order of 2000 Daltons which is negligible when compared to 
that of the hCG. The same is the case with lanes 2, 4 and 6, and additional the Glu-C digestion 
did not work very well.  
 
Since the deglycosylation and Glu-C digestion work, it will be interesting to analyze the 
fragments by Mass Spectrometry.  
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Appendix: Abbreviations and Symbols 
 
 
GPCR        G protein coupled receptor 
hCG           human choriogonadotropin 
FSH           Follicle Stimulating Hormone 
TSH          Thyroid Stimulating Hormone 
LH            Luteinizing hormone 
GnRH       Gonadotropin releasing hormone 
LH/CGR  Luteinizing hormone/ Chorionic gonadotropin hormone receptor 
FSHR        Follicle Stimulating Hormone Receptor 
GTP          Guanine Triphosphate 
GDP          Guanine diphosphate 
dg-hCG     Deglycosylated human chorionic gonadotropin 
cAMP        cyclic Adenosine mono phosphate 
Ca 2+           Calcium ions 
Asn             Asparagine 
Leu              Leucine 
LRR             Leucine rich repeats 
NHS-AB      N-hydroxysuccinimide ester of amino benzoic acid 
Bpa              4-benzoyl phenylalanine 
SES             ethylene glycolbis(sulfosuccinimidylsuccinate) 
PBS             Phosphate buffered saline 
SDS             Sodium dodecyl sulphate 
DTT            Dithiothrietol 
NaCl           Sodium chloride 
Na2HPO4     Sodium Phosphate Dibasic 
NaOH         Sodium Hydroxide 
UV             Ultra violet  
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